guest ::
| Home > Publications database > Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. > print |
| Home > Publications database > Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. > print |
| 001 | 130298 | ||
| 005 | 20240228143423.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ccell.2016.10.018 |2 doi |
| 024 | 7 | _ | |a pmid:27960088 |2 pmid |
| 024 | 7 | _ | |a 1535-6108 |2 ISSN |
| 024 | 7 | _ | |a 1878-3686 |2 ISSN |
| 024 | 7 | _ | |a altmetric:14681074 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05377 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Park, Jin-Sung |b 0 |
| 245 | _ | _ | |a Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. |
| 260 | _ | _ | |a Cambridge, Mass. |c 2016 |b Cell Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1521187219_1713 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a A destabilized tumor vasculature leads to limited drug delivery, hypoxia, detrimental tumor microenvironment, and even metastasis. We performed a side-by-side comparison of ABTAA (Ang2-Binding and Tie2-Activating Antibody) and ABA (Ang2-Blocking Antibody) in mice with orthotopically implanted glioma, with subcutaneously implanted Lewis lung carcinoma, and with spontaneous mammary cancer. We found that Tie2 activation induced tumor vascular normalization, leading to enhanced blood perfusion and chemotherapeutic drug delivery, markedly lessened lactate acidosis, and reduced tumor growth and metastasis. Moreover, ABTAA favorably altered the immune cell profile within tumors. Together, our findings establish that simultaneous Tie2 activation and Ang2 inhibition form a powerful therapeutic strategy to elicit a favorable tumor microenvironment and enhanced delivery of a chemotherapeutic agent into tumors. |
| 536 | _ | _ | |a 311 - Signalling pathways, cell and tumor biology (POF3-311) |0 G:(DE-HGF)POF3-311 |c POF3-311 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antibodies |2 NLM Chemicals |
| 650 | _ | 7 | |a Antineoplastic Agents |2 NLM Chemicals |
| 650 | _ | 7 | |a Dacarbazine |0 7GR28W0FJI |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptor, TIE-2 |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Tek protein, mouse |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Ang2 protein, mouse |0 EC 3.1.27.5 |2 NLM Chemicals |
| 650 | _ | 7 | |a Ribonuclease, Pancreatic |0 EC 3.1.27.5 |2 NLM Chemicals |
| 650 | _ | 7 | |a temozolomide |0 YF1K15M17Y |2 NLM Chemicals |
| 700 | 1 | _ | |a Kim, Il-Kug |b 1 |
| 700 | 1 | _ | |a Han, Sangyeul |b 2 |
| 700 | 1 | _ | |a Park, Intae |b 3 |
| 700 | 1 | _ | |a Kim, Chan |b 4 |
| 700 | 1 | _ | |a Bae, Jeomil |b 5 |
| 700 | 1 | _ | |a Oh, Seung Ja |b 6 |
| 700 | 1 | _ | |a Lee, Seungjoo |b 7 |
| 700 | 1 | _ | |a Kim, Jeong Hoon |b 8 |
| 700 | 1 | _ | |a Woo, Dong-Cheol |b 9 |
| 700 | 1 | _ | |a He, Yulong |b 10 |
| 700 | 1 | _ | |a Augustin, Hellmut |0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |b 11 |u dkfz |
| 700 | 1 | _ | |a Kim, Injune |b 12 |
| 700 | 1 | _ | |a Lee, Doheon |b 13 |
| 700 | 1 | _ | |a Koh, Gou Young |b 14 |
| 773 | _ | _ | |a 10.1016/j.ccell.2016.10.018 |g Vol. 30, no. 6, p. 953 - 967 |0 PERI:(DE-600)2074034-7 |n 6 |p 953 - 967 |t Cancer cell |v 30 |y 2016 |x 1535-6108 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130298 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-311 |2 G:(DE-HGF)POF3-300 |v Signalling pathways, cell and tumor biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER CELL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 20 |0 StatID:(DE-HGF)9920 |2 StatID |b CANCER CELL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)A190-20160331 |k A190 |l Vaskuläre Onkologie und Metastasierung |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A190-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|